Croda rallies into November print with earnings history on its side

Croda International heads into its November 11 results with the best one-month price performance in some time, a benign lending market, and a track record of beating expectations that gives bulls something concrete to point to.

The stock has risen 14.6% over the past month to 3,625p, adding another 2.3% this week. That recovery has come alongside a specialist chemicals sector that is broadly advancing: close peers Symrise and Sika both gained around 4% on the week, while Givaudan added 3.6%. Croda is moving with the group, not leading it, but the direction is consistent.

The lending market gives no signal of meaningful bearish pressure. Availability is extremely loose, at 3,314% of short interest, meaning there are roughly 33 shares available to borrow for every one currently borrowed. That figure has actually fallen sharply over the past week, from above 6,600% a week ago, largely because the pool of available shares has contracted rather than because new short positions have been added. Cost to borrow remains negligible at 0.60%, and the short score, a composite measure of short-side activity, has drifted only slightly higher to 50.2 from 48.2 two weeks ago. Nothing in the borrow market suggests a directional view building.

The Street picture is the more interesting tension going into the print. The consensus rating is a buy, but published price targets cluster around 37.1p (note: targets appear to be denominated in GBP, which is consistent with current price levels). The factor scoring shows a striking divergence. Forward earnings momentum ranks in the 84th percentile, and analyst recommendation dispersion ranks in the 94th percentile. Those are the marks of a stock where upgrades are concentrated and estimates are rising. Yet the EV/EBIT rank is in the 29th percentile, placing Croda near the bottom of its universe on value. The dividend score of 97 is notable, though the most recent dividend data in the available record dates to mid-2022, so that rank likely reflects the historical profile rather than a current yield assessment.

The earnings history makes a plain case for why positioning has tightened ahead of November 11. The July 2026 half-year results produced a one-day move of just over 10% and extended to 13.6% over the following five days. The prior event in May 2026 was flat. Two data points are too few to call a pattern, but the size of the July reaction is a reminder that Croda can move materially on a release. The next print will cover the second half of 2026, and with the stock having recovered sharply from what appeared to be deeply depressed levels, the focus is less on whether Croda is recovering and more on whether the recovery in margins and volumes in personal care and consumer ingredients is running fast enough to justify the re-rating already in the price.

What to watch: the November 11 release is the pivotal event, with analyst consensus sitting at buy and forward earnings momentum firmly positive. Whether the borrow market tightens materially in the final two weeks before the print, or stays as loose as it is today, will be one indicator of how much the sell side's optimism is being tested by those who disagree.